{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:27:19Z","timestamp":1794666439085,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hereditary angioedema (HAE) is a rare, autosomal disorder that manifests with unpredictable episodes of severe swelling of the skin and mucous membranes. These attacks can be highly disfiguring and range in severity from mild to\u2014in cases of airway swelling\u2014life-threatening. Fluctuations in female sex hormones\u2014such as the changes that occur during puberty, menses, contraceptive use, pregnancy, and menopause\u2014can all affect the frequency and severity of HAE attacks. Disease management decisions for women of childbearing age may be more complex and require additional considerations since they could develop complications related to contraception, pregnancy, labor, delivery, and lactation. In addition, some HAE treatment options are contraindicated during pregnancy. Discussions about medications used to treat HAE should include a risk\u2013benefit assessment of the woman\u2019s health status, her preferences, and other factors that are relevant to the choice of therapy. Planning prophylactic therapies that are effective and safe before, during, and after pregnancy can prevent gaps in treatment, ensure continuity of care, and reduce both disease burden and risk of adverse fetal outcomes. The 2020 US Hereditary Angioedema Association (HAEA) Medical Advisory Board and 2021\u00a0World Allergy Organization\/European Academy of Allergy and Immunology (WAO\/EAACI)\u00a0Guidelines outline key considerations for managing HAE in females of childbearing age (15\u201345\u00a0years), with the goal of improving treatment efficacy and safety for this cohort of patients. Treatment decisions made in a collaborative manner involving the patient, HAE specialist and obstetric\/gynecologic specialist, is the best approach to ensure optimal HAE management and safety in this patient population.<\/jats:p>","DOI":"10.1186\/s13223-022-00689-9","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T18:04:58Z","timestamp":1657735498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2201-9442","authenticated-orcid":false,"given":"Florence Ida","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lumry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Tachdjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"689_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2340\/00015555-2233","volume":"96","author":"ER Rasmussen","year":"2016","unstructured":"Rasmussen ER, de Freitas PV, Bygum A. Urticaria and prodromal symptoms including erythema marginatum in Danish patients with hereditary angioedema. Acta Derm Venereol. 2016;96:373\u20136.","journal-title":"Acta Derm Venereol"},{"key":"689_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2500\/aap.2009.30.3278","volume":"30","author":"JG Kemp","year":"2009","unstructured":"Kemp JG, Craig TJ. Variability of prodromal signs and symptoms associated with hereditary angioedema attacks: a literature review. Allergy Asthma Proc. 2009;30:493\u20139.","journal-title":"Allergy Asthma Proc"},{"key":"689_CR3","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.jaci.2018.01.015","volume":"141","author":"BL Zuraw","year":"2018","unstructured":"Zuraw BL. Hereditary angioedema with normal C1 inhibitor: four types and counting. J Allergy Clin Immunol. 2018;141:884\u20135.","journal-title":"J Allergy Clin Immunol"},{"key":"689_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/00005792-199207000-00003","volume":"71","author":"A Agostoni","year":"1992","unstructured":"Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992;71:206\u201315.","journal-title":"Medicine (Baltimore)"},{"key":"689_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","volume":"119","author":"K Bork","year":"2006","unstructured":"Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119:267\u201374.","journal-title":"Am J Med"},{"key":"689_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.iac.2013.07.006","volume":"33","author":"L Bouillet","year":"2013","unstructured":"Bouillet L, Gompel A. Hereditary angioedema in women: specific challenges. Immunol Allergy Clin North Am. 2013;33:505\u201311.","journal-title":"Immunol Allergy Clin North Am"},{"key":"689_CR7","doi-asserted-by":"publisher","first-page":"484.e1","DOI":"10.1016\/j.ajog.2008.04.034","volume":"199","author":"L Bouillet","year":"2008","unstructured":"Bouillet L, Longhurst H, Boccon-Gibod I, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199:484.e1-e4.","journal-title":"Am J Obstet Gynecol"},{"key":"689_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2217\/whe.16.6","volume":"12","author":"A Banerji","year":"2016","unstructured":"Banerji A, Riedl M. Managing the female patient with hereditary angioedema. Womens Health (Lond). 2016;12:351\u201361.","journal-title":"Womens Health (Lond)"},{"issue":"1","key":"689_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"689_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/all.15214","author":"M Maurer","year":"2022","unstructured":"Maurer M, Mageri M, Betschel S, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update. Allergy. 2022. https:\/\/doi.org\/10.1111\/all.15214.","journal-title":"Allergy"},{"issue":"4","key":"689_CR11","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.anai.2013.07.012","volume":"111","author":"L Bouillet","year":"2013","unstructured":"Bouillet L, Launay D, Fain O, et al. Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. Ann Allergy Asthma Immunol. 2013;111(4):290\u20134.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"689_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.26502\/acbr.50170078","volume":"3","author":"JE Peixoto da Costa","year":"2019","unstructured":"Peixoto da Costa JE, Oliveira Lopes JP, Souto BD, et al. The hereditary angioedema triggered by estrogen: systematic review. Arch Clin Biomed Res. 2019;3:343\u201356.","journal-title":"Arch Clin Biomed Res"},{"key":"689_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-9-44","volume":"9","author":"Z Zotter","year":"2014","unstructured":"Zotter Z, Csuka D, Szab\u00f3 E, et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2014;9:44.","journal-title":"Orphanet J Rare Dis"},{"key":"689_CR14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0002-9343(02)01526-7","volume":"114","author":"K Bork","year":"2003","unstructured":"Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med. 2003;114:294\u20138.","journal-title":"Am J Med"},{"key":"689_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S0002-9629(15)40822-5","volume":"320","author":"PG McGlinchey","year":"2000","unstructured":"McGlinchey PG, McCluskey DR. Hereditary angioedema precipitated by estrogen replacement therapy in a menopausal woman. Am J Med Sci. 2000;320:212\u20133.","journal-title":"Am J Med Sci"},{"key":"689_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejogrb.2010.05.008","volume":"152","author":"I Czaller","year":"2010","unstructured":"Czaller I, Visy B, Csuka D, et al. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol. 2010;152:44\u20139.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"131","key":"689_CR17","first-page":"e1","volume":"203","author":"I Martinez-Saguer","year":"2010","unstructured":"Martinez-Saguer I, Rusicke E, Ayg\u00f6ren-P\u00fcrs\u00fcn E, et al. Characterization of acute hereditary angioedema attacks during pregnancy and breast feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol. 2010;203(131):e1\u20137.","journal-title":"Am J Obstet Gynecol"},{"key":"689_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.18176\/jiaci.0037","volume":"26","author":"T Gonzalez-Quevedo","year":"2016","unstructured":"Gonzalez-Quevedo T, Larco JI, Marcos C, et al. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol. 2016;26:161\u20137.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"689_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jaci.2016.09.032","volume":"140","author":"K Joseph","year":"2017","unstructured":"Joseph K, Tholanikunnel BG, Kaplan AP. Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema. J Allergy Clin Immunol. 2017;140(1):170\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"689_CR20","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/sj.bjp.0701255","volume":"121","author":"P Madeddu","year":"1997","unstructured":"Madeddu P, Emanueli C, Song Q, et al. Regulation of bradykinin B2-receptor expression by oestrogen. Br J Pharmacol. 1997;121(8):1763\u20139.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"689_CR21","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1210\/endo.140.7.6871","volume":"140","author":"C Murone","year":"1999","unstructured":"Murone C, Chai SY, M\u00fcller-Esterl W, et al. Localization of bradykinin B2 receptors in the endometrium and myometrium of rat uterus and the effects of estrogen and progesterone. Endocrinology. 1999;140(7):3372\u201382.","journal-title":"Endocrinology"},{"key":"689_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/all.13001","volume":"72","author":"H Farkas","year":"2017","unstructured":"Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72:300\u201313.","journal-title":"Allergy"},{"issue":"2","key":"689_CR23","first-page":"489","volume":"60","author":"AS Coco","year":"1999","unstructured":"Coco AS. Primary dysmenorrhea. Am Fam Physician. 1999;60(2):489\u201396.","journal-title":"Am Fam Physician"},{"issue":"2","key":"689_CR24","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jaci.2011.11.025","volume":"129","author":"T Caballero","year":"2012","unstructured":"Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129(2):308\u201320.","journal-title":"J Allergy Clin Immunol"},{"key":"689_CR25","unstructured":"Kalbitor. Burlington, MA: Dyax Corp; December 2020."},{"key":"689_CR26","unstructured":"Firazyr. Lexington, MA: Takeda Pharmaceutical Company Limited; August 2020."},{"issue":"7","key":"689_CR27","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10875-018-0553-4","volume":"38","author":"R Hakl","year":"2018","unstructured":"Hakl R, Kukl\u00ednek P, Kr\u010dmov\u00e1 I, et al. Treatment of hereditary angioedema attacks with icatibant and recombinant C1 inhibitor during pregnancy. J Clin Immunol. 2018;38(7):810\u20135.","journal-title":"J Clin Immunol"},{"issue":"6","key":"689_CR28","first-page":"447","volume":"25","author":"A Zanichelli","year":"2015","unstructured":"Zanichelli A, Mansi M, Periti G. Icatibant exposure during pregnancy in a patient with hereditary angioedema. J Investig Allergol Clin Immunol. 2015;25(6):447\u20139.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"689_CR29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2500\/aap.2017.38.4038","volume":"38","author":"J Fox","year":"2017","unstructured":"Fox J, Vegh AB, Martinez-Saguer I, et al. Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema. Allergy Asthma Proc. 2017;38:216\u201321.","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"689_CR30","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.jaip.2020.03.009","volume":"8","author":"JP Brooks","year":"2020","unstructured":"Brooks JP, Radojicic C, Riedl MA, Newcomer SD, Banerji A, Hsu FI. Experience with intravenous plasma-derived C1-inhibitor in pregnant women with hereditary angioedema: a systematic literature review. J Allergy Clin Immunol Pract. 2020;8(6):1875\u201380.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"689_CR31","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1016\/j.jaip.2019.05.042","volume":"7","author":"D Moldovan","year":"2019","unstructured":"Moldovan D, Bernstein JA, Hakl R, et al. Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy. J Allergy Clin Immunol Pract. 2019;7(8):2938\u201340.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"689_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1081-1206(10)60424-3","volume":"100","author":"K Bork","year":"2008","unstructured":"Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100(2):153\u201361.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"689_CR33","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaci.2007.06.037","volume":"120","author":"DE Sloane","year":"2007","unstructured":"Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: safety of long term stanozolol therapy. J Allergy Clin Immunol. 2007;120:654\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"689_CR34","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/S1081-1206(10)60582-0","volume":"1001","author":"A Banerji","year":"2008","unstructured":"Banerji A, Sloane DE, Sheffer AL. Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2008;1001:S19\u201322.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"689_CR35","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/0091-6749(91)90120-D","volume":"87","author":"M Cicardi","year":"1991","unstructured":"Cicardi M, Bergamaschini L, Cugno M, et al. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol. 1991;87:768\u201373.","journal-title":"J Allergy Clin Immunol"},{"key":"689_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.anplas.2007.05.011","volume":"53","author":"JL Heusse","year":"2008","unstructured":"Heusse JL, Claude O, Lantieri L. Can one propose aesthetic surgery to one male or female patient with an hereditary angio-oedema? Ann Chir Plast Esthet. 2008;53:289\u201392.","journal-title":"Ann Chir Plast Esthet"},{"key":"689_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1097\/00003081-198812000-00009","volume":"31","author":"WP Dmowski","year":"1988","unstructured":"Dmowski WP. Danazol-induced pseudomenopause in the management of endometriosis. Clin Obstet Gynecol. 1988;31:829\u201339.","journal-title":"Clin Obstet Gynecol"},{"key":"689_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0015-0282(16)53638-3","volume":"54","author":"JJ Zurlo","year":"1990","unstructured":"Zurlo JJ, Frank MM. The long-term safety of danazol in women with hereditary angioedema. Fertil Steril. 1990;54:64\u201372.","journal-title":"Fertil Steril"},{"key":"689_CR39","unstructured":"Danazol. Drugs.com. https:\/\/www.drugs.com\/pro\/danazol.html. Updated March 22, 2021. Accessed 2 Aug 2021."},{"issue":"3","key":"689_CR40","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.anai.2020.10.009","volume":"126","author":"MA Riedl","year":"2021","unstructured":"Riedl MA, Banerji A, Gower R. Current medical management of hereditary angioedema: follow-up survey of US physicians. Ann Allergy Asthma Immunol. 2021;126(3):264\u201372.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"689_CR41","unstructured":"Takhzyro. Lexington, MA: Dyax Corp; November 2018."},{"key":"689_CR42","unstructured":"Orladeyo. Durham, NC: BioCryst Pharmaceuticals, Inc; December 2020."},{"issue":"3","key":"689_CR43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000467830","volume":"1","author":"PJ Sp\u00e4th","year":"1984","unstructured":"Sp\u00e4th PJ, W\u00fcthrich B, B\u00fctler R. Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema\u2014evidence of a functionally critical level of C1-inhibitor concentration. Complement. 1984;1(3):147\u201359.","journal-title":"Complement"},{"key":"689_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13223-020-0409-3","volume":"16","author":"DS Levy","year":"2020","unstructured":"Levy DS, Farkas H, Riedl M, et al. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. Allergy Asthma Clin Immunol. 2020;16:8.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"689_CR45","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jaip.2017.12.039","volume":"6","author":"WR Lumry","year":"2018","unstructured":"Lumry WR, Craig T, Zuraw B, et al. Health-related quality of life with subcutaneous C1-inhibitor for prevention of attacks of hereditary angioedema. J Allergy Clin Immunol Pract. 2018;6:1733\u201341.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"689_CR46","unstructured":"Berinert. Kankakee, IL: CSL Behring LLC; March 2021."},{"key":"689_CR47","unstructured":"Ruconest. Bridgewater, NJ: Pharming Healthcare Inc; April 2020."},{"key":"689_CR48","unstructured":"Cinryze. Lexington, MA: ViroPharma Biologics LLC; January 2021."},{"key":"689_CR49","unstructured":"Haegarda. Kankakee, IL: CSL Behring LLC; September 2020."},{"key":"689_CR50","first-page":"762","volume":"96","author":"EM Gordon","year":"1980","unstructured":"Gordon EM, Ratnoff OD, Saito H, et al. Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives. J Lab Clin Med. 1980;96:762\u20139.","journal-title":"J Lab Clin Med"},{"key":"689_CR51","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/0039-128X(96)00037-2","volume":"61","author":"F Citarella","year":"1996","unstructured":"Citarella F, Misiti S, Felici A, et al. Estrogen induction and contact phase activation of human factor XII. Steroids. 1996;61:270\u20136.","journal-title":"Steroids"},{"key":"689_CR52","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1182\/blood.V66.3.602.602","volume":"66","author":"EM Gordon","year":"1985","unstructured":"Gordon EM, Douglas JG, Ratnoff OD, Arafah BM. The influence of estrogen and prolactin on Hageman factor (factor XII) titer in ovariectomized and hypophysectomized rats. Blood. 1985;66:602\u20135.","journal-title":"Blood"},{"key":"689_CR53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0167-4781(92)90069-C","volume":"1131","author":"LM Chen","year":"1992","unstructured":"Chen LM, Chung P, Chao S, et al. Differential regulation of kininogen gene expression by estrogen and progesterone in vivo. Biochim Biophys Acta. 1992;1131:145\u201351.","journal-title":"Biochim Biophys Acta"},{"key":"689_CR54","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/0049-3848(91)90343-U","volume":"64","author":"NO Hoem","year":"1991","unstructured":"Hoem NO, Johannesen S, Hauge G, et al. Contact activation factors in plasma from women using oral contraceptives\u2014increased levels of factor XII, kinin-free high molecular weight kininogen and acetone activated kallikrein. Thromb Res. 1991;64:427\u201334.","journal-title":"Thromb Res"},{"key":"689_CR55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1471-0528.1993.tb12956.x","volume":"100","author":"SJ Campbell","year":"1993","unstructured":"Campbell SJ, Mackie IJ, Robinson GE, Machin SJ. Contact factor mediated fibrinolysis is increased by the combined oral contraceptive pill. Br J Obstet Gynaecol. 1993;100:79\u201384.","journal-title":"Br J Obstet Gynaecol"},{"key":"689_CR56","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/1047-2797(92)90093-6","volume":"2","author":"S Wessler","year":"1992","unstructured":"Wessler S. Estrogen-associated thromboembolism. Ann Epidemiol. 1992;2:439\u201343.","journal-title":"Ann Epidemiol"},{"key":"689_CR57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2500\/aap.2013.34.3635","volume":"34","author":"B Geng","year":"2013","unstructured":"Geng B, Riedl MA. HAE update: special considerations in the female patient with hereditary angioedema. Allergy Asthma Proc. 2013;34:13\u20138.","journal-title":"Allergy Asthma Proc"},{"key":"689_CR58","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000068456","volume":"206","author":"L Bouillet","year":"2003","unstructured":"Bouillet L, Ponard C, Drouet C, et al. Angioedema and oral contraception. Dermatology. 2003;206:106\u20139.","journal-title":"Dermatology"},{"key":"689_CR59","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/cea.12055","volume":"43","author":"C Saule","year":"2013","unstructured":"Saule C, Boccon-Gibod I, Fain O, et al. Benefits of progestin contraception in non-allergic angioedema. Clin Exp Allergy. 2013;43:475\u201382.","journal-title":"Clin Exp Allergy"},{"key":"689_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106080","volume":"78","author":"A Gompel","year":"2020","unstructured":"Gompel A, Fain O, Boccon-Gibod I, et al. Exogenous hormones and hereditary angioedema. Int Immunopharmacol. 2020;78: 106080.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"689_CR61","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2340\/00015555-2014","volume":"95","author":"A Bygum","year":"2015","unstructured":"Bygum A, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Beusterien K, et al. Burden of illness in hereditary angioedema: a conceptual model. Acta Derm Venereol. 2015;95(6):706\u201310.","journal-title":"Acta Derm Venereol"},{"key":"689_CR62","first-page":"2706751","volume":"2018","author":"C Tunakan Dalg\u0131\u00e7","year":"2018","unstructured":"Tunakan Dalg\u0131\u00e7 C, D\u00fc\u015f\u00fcn\u00fcr G\u00fcnsen F, Bulut G, et al. In vitro fertilization using luteinizing hormone-releasing hormone injections resulted in healthy triplets without increased attack rates in a hereditary angioedema case. Case Rep Immunol. 2018;2018:2706751.","journal-title":"Case Rep Immunol"},{"issue":"3 suppl","key":"689_CR63","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.jaci.2004.06.047","volume":"114","author":"A Agostoni","year":"2004","unstructured":"Agostoni A, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3 suppl):S51\u2013131.","journal-title":"J Allergy Clin Immunol"},{"key":"689_CR64","first-page":"54","volume":"69","author":"PG McGlinchey","year":"2000","unstructured":"McGlinchey PG, Golchin K, McCluskey DR. Life-threatening laryngeal oedema in a pregnant woman with hereditary angioedema. Ulster Med J. 2000;69:54\u20137.","journal-title":"Ulster Med J"}],"updated-by":[{"DOI":"10.1186\/s13223-022-00714-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000}}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-022-00689-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-022-00689-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-022-00689-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T13:05:48Z","timestamp":1662210348000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-022-00689-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["689"],"URL":"https:\/\/doi.org\/10.1186\/s13223-022-00689-9","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"12 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13223-022-00714-x","URL":"https:\/\/doi.org\/10.1186\/s13223-022-00714-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Hsu: Consultant- Antares, BioCryst, Intellia, KalVista, Takeda. Speaker- CSL Behring, Pharming, Takeda. Research support- Takeda. Dr. Lumry: Consultant- Accordant, BioCryst, BioMarin, CSL Behring, Express Scripts, Fresenius Kabi, Intellia, KalVista, Magellan, Optum, Pharming, Pharvaris, Shire\/Takeda. Speaker- BioCryst, CSL Behring, Pharming, Shire\/Takeda, Grifols, Astra Zeneca, Sanofi\/Regeneron, GSK. Research Support- ALK, BioCryst, BioMarin, CSL Behring, Gossamer, Green Cross, Grifols, Ionis, KalVista, Kedrion, Menlo, Shire\/Takeda, Teva, Therapure. US Hereditary Angioedema Association (US HAEA) Medical Advisory Board Member (uncompensated). Dr. Riedl: Consultant- Astria, BioCryst, BioMarin, CSL Behring, Cycle Pharma, Fresenius-Kabi, Ipsen, KalVista, Ono Pharma, Pfizer, Pharming, Pharvaris, RegenexBio, Sanofi-Regeneron, Takeda. Speaker- CSL Behring, Grifols, Pharming, Takeda. Research support-BioCryst, BioMarin, CSL Behring, Ionis, KalVista, Pharvaris, Takeda. US HAEA Medical Advisory Board Member (uncompensated). Dr. Tachdjian: Consultant- BioCryst, CSL Behring, Pharming, Takeda. Speaker- BioCryst, CSL Behring, Pharming, Takeda. Research support-BioCryst, Ionis, KalVista, Pharvaris, Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}